Dynamic Metrics

Compliance Team
Angels Den

Dear User,

You may have heard about the new General Data Protection Regulation (“GDPR”), that comes into effect May 25, 2018.

We would like to ensure you that your personal data is safe with us. Please read the details regarding the processing of your personal data and if you agree with the processing as described below, please click the ‘I agree’ button.

Please be informed that you can withdraw this consent at any time.

1) What data are we talking about?

We are disclosing details regarding the processing of personal data that is collected within our calls and in connection with your use of Angels Den’s platform, Websites and other functionalities of Angels Den, including those saved in cookies files.

2) Who will be the controller of your data?

Angels Den Funding Limited (hereinafter referred to as AD) will be the controller of your data (Angels Den means all entities from the Angels Den capital group, which includes Angels Den Funding Limited with its registered office in London and all entities related to it and dependent on it) and only our Trusted Partners.

3) Why do we want to process your data?

We process this data for the purposes described in our Privacy Policy, including:
- compliance with any legal requirements and obligations,
- ensuring that content from our Website is presented in the most effective manner for you,
- marketing purposes,
- providing you with our services (including the completion and support of immediate activity required to provide you with information and deliver products and/or services that you request and to deliver any contracts entered into with you), or
- as otherwise explained in this privacy policy or by any communication by us.
Where you have explicitly consented to be contacted for such purposes, we use your personal data to provide information on our new and existing products and services.

4) To whom can we transfer data?

In accordance with applicable law, we may transfer your data to entities processing it at our request, e.g. marketing agencies, subcontractors of our services and entities authorized to obtain data under applicable law, e.g. courts or law enforcement agencies - of course only if they submit a request based on an applicable legal basis. Furthermore, we will transfer your data to Trusted Partners outside the European Union – to the USA – under the EU-U.S. Privacy Shield Framework.

5) What are your rights to your data?

You have the right to request access to, correct, delete your personal data. You can also withdraw consent to processing of personal data, raise objections and use other rights granted under GDPR (i.e. right to data portability).

6) Use of cookies

We use cookies to give you the best experience on our Website. This means that we have placed cookies on your device. If you continue without changing your cookie settings, we assume that you consent to our use of cookies on this device. You can change your cookie settings at any time but if you do, you may lose some functionality on our Website. More information can be found in our Privacy Policy.

In connection with the above, I agree to the processing of my personal data by Angels Den and its Trusted Partners. I confirm that I understand that my personal data is being collected as part of my phone calls, use of AD’s online platform, Websites, and other functionalities of AD, including the data saved in cookie files. I also consent to profiling in order to allow Angels Den and its Trusted Partners the provision of better services (including for analytical purposes). Your data will only be processed on a valid lawful basis in accordance with applicable data protection laws. The processing of your personal data for marketing purposes (including statistical analysis) by AD is based on the firm's legitimate interest. The processing for marketing purposes by our Trusted Partners is only possible if we receive your freely given consent. We will also process your personal data to fulfil our contractual obligations to you as contained in AD’s Terms and Conditions of the use of our Website and services. Therefore, this data will be processed on another lawful basis – ‘contract’. We will also process your data to comply with our legal obligations for our Service (such as anti money laundering and know your customer requirements), which is also a valid lawful basis in accordance with applicable data protection laws.

Expressing this consent is voluntary and you can withdraw at any time.

If you have any doubts or questions about the use of your personal data, please do not hesitate to contact me via email. I’m happy to assist.

Compliance Team
Angels Den
cl@angelsden.com

I Agree

Not Now

DYNAMIC METRICS

Early-stage sensor-based tech company with revenues and strong sales pipeline seeking funds for the launch of 2nd gen gait assessment system (CE, 1M) being used in pharma clinical trials and NHS.

£ 215,000

0 Days left

215% of minimum goal raised

Mark Tousey

Minimum Target

£ 100,000

Minimum investment amount

£ 10,000

Maximum Target

£ 500,055

Maximum investment amount

£ 300,000

Investment Opportunity

Dynamic Metrics (DML) sets the reference standard for assessing physical movement so that motion can join blood chemistry, BP, BMI and cholesterol levels as part of the standard health baseline. Billion-pound+ markets for the company's products and technology platform include clinical trials (drugs, devices and diagnostics), healthcare (elderly falls, osteoarthritis and back pain) and tech licensing. DML is an early-stage company with proven, patented technology, 3 commercial products and a robust R&D pipeline. The Company is ISO 13485 and 9001 certified and has generated growing sales and sales pipeline. With this funding, DML expects to be cashflow positive in 2019 and profitable in 2020.

THE IDEA

Products & Services

DML’s portable GaitSmart system is a CE marked Class 1M medical device that quickly and accurately measures the full motion of walking. Customers include a major pharma (market cap $40bn+) where GaitSmart is being used in a multi-site clinical trial for a new osteoarthritis drug. In NHS England and NHS Scotland, GaitSmart tests are supplemented with vGym, a software add-on that provides exercises tailored to individual gait parameters, to reduce the risk of falls in the elderly. The next product will be SpineSmart to tackle the immense back pain market. Future R&D includes the use of AI to define gait patterns for the early detection of neurological conditions, including dementia.

Problem Solved

Some of the biggest healthcare challenges such as falls in the elderly, osteoarthritis and back pain require the ability to measure motion and compare against a healthy reference. DML’s GaitSmart system is simple, portable and accurately measures and assesses the full motion of walking. vGym software tailors’ exercises to individual gait readings. GaitSmart provides cost-effective endpoints for clinical trials so that life science companies have objective data to prove the effectiveness of their drug, diagnostic test or medical device. GaitSmart and vGym provide an alternative that has been proven to reduce falls/improve post joint rehab, with positive budget impacts.

Revenue Model

Clinical trials market: life science companies use GaitSmart as a clinical endpoint in the development, validation and/or distribution of their products and services. DML charges an annual leasing fee for the hardware plus a per/person fee. Customers generally become repeat customers for further phases of the trial or for new trials. Healthcare: DML charges an annual leasing fee plus per/test fee. Because of the simplicity of the test, providers can be pharmacies, gyms, retail stores. Payers can be public or private (insurance, employers). Tech licensing fees will range from royalties for database or software use to revenue sharing for co-development of new products using DML tech.